Search Results

Rhythm Pharmaceuticals, Inc. announced that on June 6, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement equity grants covering an aggregate of 56,080 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 9,230 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 46,850 shares of its common stock.

Rhythm Pharmaceuticals, Inc. announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees.

CIRCA Scientific, Inc., a pioneer in the development of esophageal temperature monitoring, will be attending Heart Rhythm 2024 to showcase the company’s latest technologies for Cardiac Electrophysiology.

Rhythm Pharmaceuticals, Inc. today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m.

Rhythm Pharmaceuticals, Inc. reported financial results and provided a business update for the first quarter ended March 31, 2024.

OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood pressure monitor with ECG technology, Complete, and a series of home-use blood pressure monitors.

Rhythm Pharmaceuticals, Inc. announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 14,740 shares of its common stock.

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients’ quality of life while reducing costs to healthcare systems.